Peanut Allergy Pipeline Insight

DelveInsight’s, “Peanut Allergy - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Peanut Allergy Understanding

Peanut Allergy: Overview

A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system —the body's natural defense system that fights infections and diseases—overreacts and can cause a serious, even life-threatening response. Symptoms of peanut allergy can range from mild to severe. If you have a mild reaction, you may get a stomachache, a runny nose, itchy eyes, hives, or tingling in your lips or tongue. Your symptoms may start from within a few minutes to a few hours after eating peanuts or peanut products.


Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.

Peanut Allergy Emerging Drugs Chapters

This segment of the Peanut Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Peanut Allergy Emerging Drugs


Viaskin Peanut: DBV Technologies

DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. It is currently in preregistration stage of development.


Dupilumab: Regeneron Pharmaceuticals/Sanofi

Dupilumab is a IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in phase II stage of development.


CNP-201: Cour Pharmaceutical

CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy. It is currently in phase I/II stage of development.

Further product details are provided in the report……..

Peanut Allergy: Therapeutic Assessment

This segment of the report provides insights about the different Peanut Allergy drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Peanut Allergy

There are approx. 15+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include, DBV Technologies.

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intradermal
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peanut Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peanut Allergy therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peanut Allergy drugs.

Peanut Allergy Report Insights

  • Peanut Allergy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Peanut Allergy Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Peanut Allergy drugs?
  • How many Peanut Allergy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peanut Allergy and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Peanut Allergy: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Preregistration)

  • Comparative Analysis

Viaskin Peanut: DBV Technologies

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Dupilumab: Regeneron Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

CNP-201: Cour Pharmaceutical

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Peanut-NE01 vaccine: BlueWillow Biologics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Peanut Allergy Key Companies

Peanut Allergy Key Products

Peanut Allergy- Unmet Needs

Peanut Allergy- Market Drivers and Barriers

Peanut Allergy- Future Perspectives and Conclusion

Peanut Allergy Analyst Views

Peanut Allergy Key Companies

Appendix

List of Table

Table 1: Total Products for Peanut Allergy

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Peanut Allergy

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• DBV Technologies

• Regeneron Pharmaceuticals

• Cour Pharmaceutical

• HAL Allergy

• InnoUp Farma S.L.

• Vedanta Biosciences

• Astellas Pharma

• Intrommune Therapeutics

• Genentech

• ASIT biotech

• BlueWillow Biologics

• Allergy Therapeutics

• Alladapt Immunotherapeutics

• Desentum

• Camallergy

• Prota Therapeutics

• IgGenix

  • Tags:
  • "Peanut Allergy Pipeline
  • Peanut Allergy clinical trials
  • Peanut Allergy companies
  • Peanut Allergy drugs
  • Peanut Allergy therapies
  • Peanut Allergy treatment algorithm
  • Peanut Allergy pipeline drugs
  • Peanut Allergy pipeline companies...

Forward to Friend

Need A Quote